Strongbridge Bio Ord (SBBP)

Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.

DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”)...

Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.

Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.

Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris

Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris

Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals

INVESTIGATION: Halper Sadeh LLP Investigates SBBP, QTS, GRA, SWN, ONEM, IKNX; Shareholders are Encouraged to Contact the Firm

Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement

Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue

Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021

Strongbridge Biopharma (SBBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strongbridge Biopharma plc Announces Dates of Special Shareholder Meetings in Connection with the Proposed Acquisition by Xeris Pharmaceuticals, Inc.

Axogen, Inc. Appoints John H. Johnson to Board of Directors

Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors

Strongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve

INVESTIGATION ALERT: Halper Sadeh LLP Investigates SBBP, RFL, CLDB, MPB; Shareholders are Encouraged to Contact the Firm

SHAREHOLDER ALERT: WeissLaw LLP Reminds SLCT, DISCA, LORL, SBBP Shareholders About Its Ongoing Investigations

INVESTIGATION ALERT: Halper Sadeh LLP Investigates RAVN, RIVE, ESXB, ICON, SBBP; Shareholders are Encouraged to Contact the Firm

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigation of CLDR, KSU, SBBP, and DISCA Mergers

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates MMAC, XEC, SBBP, SLCT; Shareholders are Encouraged to Contact the Firm

SHAREHOLDER ALERT: WeissLaw LLP Reminds KNL, DTRC, SBBP, and CNST Shareholders About Its Ongoing Investigations

INVESTIGATION ALERT: Halper Sadeh LLP Investigates NCBS, SHSP, CLDB, SBBP; Shareholders are Encouraged to Contact the Firm

SHAREHOLDER ALERT: WeissLaw LLP Reminds MMAC, SBBP, HRVSF, and XOG Shareholders About Its Ongoing Investigations

INVESTIGATION ALERT: Halper Sadeh LLP Investigates FBNC, AVCO, XEC, CLDR, SBBP; Shareholders are Encouraged to Contact the Firm

SHAREHOLDER ALERT: WeissLaw LLP Reminds SNX, MMAC, SBBP, and HRVSF Shareholders About Its Ongoing Investigations

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ARPO, ALTA, MMAC, SBBP; Shareholders are Encouraged to Contact the Firm

SHAREHOLDER ALERT: WeissLaw LLP Reminds MMAC, SBBP, HRVSF, and XOG Shareholders About Its Ongoing Investigations

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates TGRF, SLCT, ESXB, SBBP, MX; Shareholders are Encouraged to Contact the Firm

Lifshitz Law Firm, P.C. Announces Investigation of CLDR, DTRCD, DCRN, ENVB, PACX, SNX, XERS, and SBBP

Strongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoketoconazole) for the Treatment of Cushing’s Syndrome